Patients with diabetes rely on certain devices for their daily management, and it is vital that they have confidence in the safety and effectiveness of their products. On today's episode, Hosts Danielle Kirsh and Sean Whooley detail how medtech giant Medtronic resolved its earlier FDA warning letter related to its diabetes business.

GE Healthcare recently launched its next-generation intraoperative ultrasound technology, a significant advancement in medical imaging. Whooley discusses how the technology could streamline physician workflow in the operating room.

Non-invasive biometric monitoring is on the horizon. Fast Five hosts Kirsh and Whooley discuss CardieX's recent FDA clearance and how it could allow healthcare providers to monitor blood pressure and central blood pressure using arterial waveform analysis.

Despite an earnings season full of economic headwinds, Boston Scientific nearly tripled its profits in Q1. This is a positive sign for the medical device industry as it indicates a healthy market and ongoing innovation. Whooley gives an in-depth look at the company's financial performance and how optimistic CEO Mike Mahoney is.

Finally, Medtronic's Endurant stent graft system showed durable outcomes in a 10-year post-market registry. Shown to be safe and effective, Whooley details what the device is indicated for and how it could lead to improved patient outcomes and a better quality of life.

Check out the show notes at massdevice.com/podcast.